A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

Inclusion Criteria:

• Documented multiple myeloma as defined: a) Multiple myeloma diagnosis according tothe International Myeloma Working Group (IMWG) diagnostic criteria and b) Measurabledisease at screening as defined by any of the following: i) Serum M-protein levelgreater than or equal to (>=) 0.5 grams per deciliter (g/dL) (central laboratory);ii) Urine M-protein level >= 200 milligram (mg) per 24 hours (central laboratory);iii) Light chain multiple myeloma without measurable M-protein in the serum or theurine: serum immunoglobulin free light chain >= 10 milligram per deciliter (mg/dL) (central laboratory), and abnormal serum immunoglobulin kappa lambda free lightchain ratio

• Relapsed or refractory disease as defined by: i) Relapsed disease is defined as aninitial response to prior treatment, followed by confirmed progressive disease byIMWG criteria greater than (>) 60 days after cessation of treatment; ii) Refractorydisease is defined as less than (<) 25 percent (%) reduction in monoclonalparaprotein (M-protein) or confirmed progressive disease by IMWG criteria duringprevious treatment or less than or equal to (<=) 60 days after cessation oftreatment

• Received at least 1 prior line of antimyeloma therapy including a proteasomeinhibitor (PI) and lenalidomide. Participants who have received only 1 prior line ofantimyeloma therapy must be considered lenalidomide-refractory (that is, havedemonstrated progressive disease by IMWG criteria on or within 60 days of completionof lenalidomide-containing regimen). Participants who have received >=2 prior linesof antimyeloma therapy must be considered lenalidomide exposed

• Documented evidence of progressive disease based on investigator's determination ofresponse by the IMWG criteria on or after their last regimen

• Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1,or 2 at screening and immediately prior to the start of administration of studytreatment

Exclusion Criteria:

• Contraindications or life-threatening allergies, hypersensitivity, or intolerance tostudy drug excipients

• Disease is considered refractory to an anti-cluster of differentiation 38 (CD38)monoclonal antibody as defined per IMWG consensus guidelines (progression duringtreatment or within 60 days of completing therapy with an anti-CD38 monoclonalantibody)

• Received prior pomalidomide therapy

• A maximum cumulative dose of corticosteroids to >=140 milligrams (mg) of prednisoneor equivalent within 14-day period before the first dose of study drug

• Known active central nervous system (CNS) involvement or exhibits clinical signs ofmeningeal involvement of multiple myeloma. If either is suspected, negative wholebrain magnetic resonance imaging (MRI) and lumbar cytology are required

• Plasma cell leukemia (per IMWG criteria) at the time of screening, Waldenström'smacroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, M-protein, and skinchanges (POEMS syndrome), or primary amyloid light chain amyloidosis